Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-Resistant Enterococcus faecium Meningitis and Bacteremia
dc.contributor.author | Wenzler, Eric | |
dc.contributor.author | Adeel, Alina | |
dc.contributor.author | Wu, Tiffany | |
dc.contributor.author | Jurkovic, Michele | |
dc.contributor.author | Walder, Jeremy | |
dc.contributor.author | Ramasra, Emily | |
dc.contributor.author | Campion, Maureen | |
dc.contributor.author | Cerny, Jan | |
dc.contributor.author | Theodoropoulos, Nicole M. | |
dc.date | 2022-08-11T08:10:06.000 | |
dc.date.accessioned | 2022-08-23T16:55:23Z | |
dc.date.available | 2022-08-23T16:55:23Z | |
dc.date.issued | 2021-09-08 | |
dc.date.submitted | 2022-06-02 | |
dc.identifier.citation | <p>Wenzler E, Adeel A, Wu T, Jurkovic M, Walder J, Ramasra E, Campion M, Cerny J, Theodoropoulos NM. Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-Resistant <em>Enterococcus faecium</em> Meningitis and Bacteremia. Infect Dis Rep. 2021 Sep 8;13(3):843-854. doi: 10.3390/idr13030076. PMID: 34563001; PMCID: PMC8482274. <a href="https://doi.org/10.3390/idr13030076">Link to article on publisher's site</a></p> | |
dc.identifier.issn | 2036-7430 (Linking) | |
dc.identifier.doi | 10.3390/idr13030076 | |
dc.identifier.pmid | 34563001 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/42703 | |
dc.description.abstract | BACKGROUND: Vancomycin-resistant Enterococcus faecium (VRE) in particular has evolved as an important cause of hospital acquired infection, especially in immunocompromised hosts. METHODS: We present a complex case of a patient with relapsed acute myeloid leukemia who underwent allogenic hematopoietic stem cell transplantation complicated by persistent VRE bacteremia and meningitis. To optimize therapy, various blood and cerebrospinal fluid (CSF) samples were sent to a research laboratory for extensive susceptibility testing, pharmacokinetic analyses, and time-kill experiments. RESULTS: In vitro testing revealed resistance to all first-line treatment options and CSF sampling demonstrated sub-optimal central nervous system concentrations achieved by each antimicrobial agent administered in relation to their respective MIC value. Time-kill analyses at observed CSF concentrations confirmed the lack of bactericidal activity despite use of a four-drug combination regimen. CONCLUSIONS: This work is the first to report CSF concentrations of oritavancin and tedizolid in humans and adds to the limited data regarding in vitro susceptibility of new antimicrobial agents such as eravacycline, omadacycline, and lefamulin against VRE. Our study provides new insights into various aspects of treatment of extensively drug-resistant Enterococcus faecium meningitis and bacteremia and supports the continued pursuit of precision medicine for these challenging cases. | |
dc.language.iso | en_US | |
dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34563001&dopt=Abstract">Link to Article in PubMed</a></p> | |
dc.rights | Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Enterococcus faecium | |
dc.subject | VRE | |
dc.subject | case report | |
dc.subject | central nervous system | |
dc.subject | cerebrospinal fluid | |
dc.subject | meningitis | |
dc.subject | pharmacokinetics | |
dc.subject | time-kill analysis | |
dc.subject | Bacterial Infections and Mycoses | |
dc.subject | Hematology | |
dc.subject | Immunology and Infectious Disease | |
dc.subject | Infectious Disease | |
dc.title | Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-Resistant Enterococcus faecium Meningitis and Bacteremia | |
dc.type | Journal Article | |
dc.source.journaltitle | Infectious disease reports | |
dc.source.volume | 13 | |
dc.source.issue | 3 | |
dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5982&context=oapubs&unstamped=1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/4947 | |
dc.identifier.contextkey | 29511279 | |
refterms.dateFOA | 2022-08-23T16:55:23Z | |
html.description.abstract | <p>BACKGROUND: Vancomycin-resistant Enterococcus faecium (VRE) in particular has evolved as an important cause of hospital acquired infection, especially in immunocompromised hosts.</p> <p>METHODS: We present a complex case of a patient with relapsed acute myeloid leukemia who underwent allogenic hematopoietic stem cell transplantation complicated by persistent VRE bacteremia and meningitis. To optimize therapy, various blood and cerebrospinal fluid (CSF) samples were sent to a research laboratory for extensive susceptibility testing, pharmacokinetic analyses, and time-kill experiments.</p> <p>RESULTS: In vitro testing revealed resistance to all first-line treatment options and CSF sampling demonstrated sub-optimal central nervous system concentrations achieved by each antimicrobial agent administered in relation to their respective MIC value. Time-kill analyses at observed CSF concentrations confirmed the lack of bactericidal activity despite use of a four-drug combination regimen.</p> <p>CONCLUSIONS: This work is the first to report CSF concentrations of oritavancin and tedizolid in humans and adds to the limited data regarding in vitro susceptibility of new antimicrobial agents such as eravacycline, omadacycline, and lefamulin against VRE. Our study provides new insights into various aspects of treatment of extensively drug-resistant Enterococcus faecium meningitis and bacteremia and supports the continued pursuit of precision medicine for these challenging cases.</p> | |
dc.identifier.submissionpath | oapubs/4947 | |
dc.contributor.department | Department of Medicine, Division of Hematology Oncology | |
dc.contributor.department | Department of Medicine, Division of Infectious Diseases and Immunology | |
dc.source.pages | 843-854 |